Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E. 07:43:54 2024-07-19 EDT 5-day change 1st Jan Change
335.2 INR -2.33% Intraday chart for Biocon Limited -4.43% +34.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
India plans incentives for diabetes, obesity drug makers in 2026, government official says RE
EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites CI
Biocon Arm Gets European Regulator's Nod to Manufacture Bevacizumab at Indian Facility MT
Biocon Gets Four Observations from US FDA for Visakhapatnam, India Facility MT
India's Biocon seeks partner to test generic Wegovy, Ozempic in China RE
Biocon Gets Three Observations from US FDA after Visakhapatnam, India Unit Inspection MT
Indian Equities End Flat on Tuesday; ONGC Shares Rise 6% MT
Biocon Names Interim CFO MT
Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer CI
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Biocon Limited Receives Approval from the U.S. Food and Drug Administration CI
Biocon Limited Receives Show Cause Notice from the Assistant Commissioner of Customs, Chennai CI
INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh RE
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea MT
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc CI
US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz MT
Jefferies Adjusts Biocon’s Price Target to INR230 From INR250, Keeps at Underperform MT
Biocon's Consolidated Net Profit Declines in Fiscal Q4 MT
India's Biocon posts Q4 profit fall as higher raw material costs bite RE
Transcript : Biocon Limited, Q4 2024 Earnings Call, May 16, 2024
Biocon Limited Proposes Final Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024 CI
Biocon Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Biocon Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico MT
Biocon Limited Signs Semi-Exclusive Distribution and Supply Deal for the Commercialization of Generic Saxenda® (Liraglutide) in Mexico with Medix CI
Chart Biocon Limited
More charts
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
335.2 INR
Average target price
310 INR
Spread / Average Target
-7.52%
Consensus